Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-05-01 DOI:10.21873/invivo.13952

Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Ryuki Esashi, Sosuke Yamamoto, Kiyoko Shimada, Keisuke Kazama, Ayako Tamagawa, Mie Tanabe, Keisuke Komori, Natsumi Kamiya, Naoko Okuda, Koji Numata, Mamoru Uchiyama, Aya Saito, Norio Yukawa

{"title":"Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.","authors":"Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Ryuki Esashi, Sosuke Yamamoto, Kiyoko Shimada, Keisuke Kazama, Ayako Tamagawa, Mie Tanabe, Keisuke Komori, Natsumi Kamiya, Naoko Okuda, Koji Numata, Mamoru Uchiyama, Aya Saito, Norio Yukawa","doi":"10.21873/invivo.13952","DOIUrl":null,"url":null,"abstract":"Background/aim: Body composition changes and nutritional status affect the oncological outcomes in various malignancies. Modified advanced lung cancer inflammation index (mALI) evaluates both body composition changes and nutritional status. Herein, we aimed to examine the potential of mALI as a biomarker for gastric cancer (GC).Patients and methods: The medical records of 327 consecutive patients with gastric cancer who underwent curative resection at Yokohama City University from 2015 to 2022 were retrospectively reviewed. mALI was defined follows: Appendicular skeletal muscle index×Serum albumin/Neutrophil-to-lymphocyte ratio. The clinical impact of the mALI on the short- and long-term oncological outcomes was evaluated using Kaplan-Meier curves and Cox's proportional hazards models.Results: The 327 patients were classified into the mALI-low (n=121) and mALI-high (n=206) groups, respectively. The 1-, 3-, and 5-year overall survival (OS) rates were 94.0%, 71.4%, and 59.2%, respectively, in the mALI-low group, and 95.5%, 85.0%, and 79.9%, in the mALI-high group. In the multivariable analysis for OS, the mALI was identified as an independent prognostic factor [hazard ratio (HR)=1.794; 95% confidence interval (CI)=1.155-2.786, p=0.009]. The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 79.6%, 66.0%, and 54.3%, respectively, in the mALI-low group, and 90.7%, 79.1%, and 75.5% in the mALI-high group. The multivariable analysis of RFS, identified the mALI as an independent prognostic factor (HR=1.654; 95% CI=1.105-2.477, p=0.015). In addition, the mALI status affected short-term oncological outcomes, including the occurrence of postoperative surgical complications and the introduction of postoperative adjuvant chemotherapy.Conclusion: The mALI was an independent prognostic factor for OS and RFS in patients with GC. Our results suggest that the mALI is a promising biomarker for GC and a useful tool for the treatment and management of GC.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1524-1532"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13952","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Body composition changes and nutritional status affect the oncological outcomes in various malignancies. Modified advanced lung cancer inflammation index (mALI) evaluates both body composition changes and nutritional status. Herein, we aimed to examine the potential of mALI as a biomarker for gastric cancer (GC).

Patients and methods: The medical records of 327 consecutive patients with gastric cancer who underwent curative resection at Yokohama City University from 2015 to 2022 were retrospectively reviewed. mALI was defined follows: Appendicular skeletal muscle index×Serum albumin/Neutrophil-to-lymphocyte ratio. The clinical impact of the mALI on the short- and long-term oncological outcomes was evaluated using Kaplan-Meier curves and Cox's proportional hazards models.

Results: The 327 patients were classified into the mALI-low (n=121) and mALI-high (n=206) groups, respectively. The 1-, 3-, and 5-year overall survival (OS) rates were 94.0%, 71.4%, and 59.2%, respectively, in the mALI-low group, and 95.5%, 85.0%, and 79.9%, in the mALI-high group. In the multivariable analysis for OS, the mALI was identified as an independent prognostic factor [hazard ratio (HR)=1.794; 95% confidence interval (CI)=1.155-2.786, p=0.009]. The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 79.6%, 66.0%, and 54.3%, respectively, in the mALI-low group, and 90.7%, 79.1%, and 75.5% in the mALI-high group. The multivariable analysis of RFS, identified the mALI as an independent prognostic factor (HR=1.654; 95% CI=1.105-2.477, p=0.015). In addition, the mALI status affected short-term oncological outcomes, including the occurrence of postoperative surgical complications and the introduction of postoperative adjuvant chemotherapy.

Conclusion: The mALI was an independent prognostic factor for OS and RFS in patients with GC. Our results suggest that the mALI is a promising biomarker for GC and a useful tool for the treatment and management of GC.

查看原文本刊更多论文

改良晚期肺癌炎症指数是胃癌患者接受根治性治疗的独立预后因素。

背景/目的：机体成分变化和营养状况影响各种恶性肿瘤的预后。改进的晚期肺癌炎症指数（mALI）评估身体成分变化和营养状况。在此，我们旨在研究马里作为胃癌（GC）生物标志物的潜力。患者和方法：回顾性分析2015 - 2022年横滨市立大学327例连续行根治性胃癌切除术患者的病历。马里的定义如下：阑尾骨骼肌index×Serum白蛋白/中性粒细胞与淋巴细胞的比值。使用Kaplan-Meier曲线和Cox比例风险模型评估mALI对短期和长期肿瘤预后的临床影响。结果：327例患者分别分为低马利组（n=121）和高马利组（n=206）。mALI-low组的1、3、5年总生存率（OS）分别为94.0%、71.4%和59.2%，mALI-high组的OS分别为95.5%、85.0%和79.9%。在OS的多变量分析中，马里被确定为一个独立的预后因素[危险比(HR)=1.794；95%置信区间(CI)=1.155 ~ 2.786, p=0.009]。mALI-low组1、3、5年无复发生存率（RFS）分别为79.6%、66.0%和54.3%，mALI-high组为90.7%、79.1%和75.5%。RFS的多变量分析表明，马里是一个独立的预后因素(HR=1.654；95% CI=1.105 ~ 2.477, p=0.015)。此外，马里状态影响短期肿瘤预后，包括术后手术并发症的发生和术后辅助化疗的引入。结论：mALI是胃癌患者OS和RFS的独立预后因素。我们的结果表明，mALI是一种很有前途的GC生物标志物，也是一种治疗和管理GC的有用工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.